Britain and America have agreed to a landmark bilateral deal that will maintain no levies on British medicine exports being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the NHS. This pledge ensures that import taxes on these crucial goods will stay at nothing for a duration of the next three years.
This development is in response to previous threats to hike import taxes on patented drug products, with potential rates mentioned reaching 100%.
"This agreement between the United Kingdom bolsters the global environment for new treatments and introduces much-needed equity to transatlantic drug exports," a statement said.
Economic Impact
Medicines are one of the the United Kingdom's most significant export categories to the US, which is easily the largest destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the year leading up to September, the UK exported medicines totaling over eleven billion pounds to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards employment, increases capital expenditure and sets the stage for the UK to become a global hub for biotech and pharma," a minister stated.
Specific British Pledges
The agreement includes several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Previously, refunds exceeded twenty percent.
Recent Tensions
This agreement takes place against a protracted row between the drug companies and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by claims that US customers were paying a premium for the same drugs than people in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
